Supplementary Figure 3 from CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma

Ghassan K. Abou‐Alfa; Susan M. Geyer; Andrew B. Nixon; Federico Innocenti; Qian Shi; Priya Kumthekar; Sawyer Jacobson; Imane El Dika; Amin Yaqubie; Juan Lopez; Binhui Huang; Yi‐Wei Tang; Yujia Wen; Lawrence H. Schwartz; Anthony B. El-Khoueiry; Jennifer J. Knox; Lakshmi Rajdev; Monica M. Bertagnolli; Jeffrey A. Meyerhardt; Eileen M. O’Reilly; Alan P. Venook

doi:10.1158/2767-9764.25359909.v1

Abstract

Supplementary Figure 3. Kaplan-Meier curves for the progression-free survival distributions for patients who have detectable (HCV-D) vs. undetectable (HCV-UN) HCV titer levels on their first evaluated sample, by treatment arm.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Abou‐Alfa et al. (2024) studied this question.

synapsesocial.com/papers/68e7556db6db6435876cd688 https://doi.org/10.1158/2767-9764.25359909.v1

View Full Paper

Ask AI

Bookmark

Share

Supplementary Figure 3 from CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma

Abstract

Discussion

Cite This Study

Supplementary Figure 3 from CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma

Abstract

Discussion

Cite This Study

Keep reading

More related papers

Keep reading

More related papers